Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Rivaroxaban Compared With Apixaban in Cancer-Associated Venous Thromboembolism: A Head-to-Head (H2H) Analysis of the United States Cohort of the Observational Study in Cancer Associated Thrombosis for Rivaroxaban (H2H-OSCAR-US)

NCT05461807 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05461807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05461807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Rivaroxaban Compared With Apixaban in Cancer-Associated Venous Thromboembolism: A Head-to-Head (H2H) Analysis of the United States Cohort of the Observational Study in Cancer Associated Thrombosis for Rivaroxaban (H2H-OSCAR-US)
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
July 14, 2022
Completion date
October 5, 2022
Enrollment
2,437 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, treatment of venous thromboembolism in cancer patients, venous thromboembolism